A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
A narrative review of the management of BRAF non-V600E mutated metastatic non-small cell lung cancer
Precision Cancer Medicine
and Objective: V-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations occur in approximately 2-4% of patients with non-small cell lung cancer (NSCLC). BRAF non-V600E mutant NSCLC is a rare entity that has yet to be fully characterized. The treatment paradigm is evolving and is currently often extrapolated from data pertaining to V600E mutations. This article serves as a comprehensive review of the clinical characteristics, prognosis, current management and treatment algorthim fordoi:10.21037/pcm-21-49 fatcat:uhj2dvd5xrhi7jo7oei4esskbq